Skip to content
COA & Batch Documentation Available Explore Research Peptides
Batch Tested IGF-1 LR3
HPLC Verified COA Included AU Dispatch
Research Grade Independently Tested

IGF-1 LR3

Verified Synthesis Batch COA Available
≥ 99% (HPLC) CAS 946870-92-4 C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
$134.99 AUD · GST incl.
  • Certificate of Analysis available for every batch
  • Form: Lyophilised Powder
  • Storage: 2°C-8°C (Refrigerated)
  • Australia-wide, discreet tracked dispatch
  • Research Use Only - not for human or veterinary use

IGF-1 LR3 Peptide is a modified form of insulin-like growth factor 1 used in lab investigations for its involvement with IGF-1 receptor signaling mechanisms, cell proliferation studies, and metabolism model systems. The IGF-1 LR3 1mg research vial is formulated as lyophilized peptide substance for laboratory investigation only.

What Is IGF-1 LR3?

Long R3 IGF-1 is another name for the IGF-1 LR3. The compound has structural differences from the native insulin-like growth factor 1 because it has a longer amino acid chain and an altered arginine. The changes are researched since they can affect the binding, stability, and interactions with IGF-binding proteins.

Regarding the study of peptides, Long R3 IGF-1 is usually studied in connection with the IGF-1 receptor activation, cell proliferation, protein synthesis, glucose uptake mechanisms, and growth factor signaling. It is neither drug, dietary supplement nor cosmetic.

Why Is IGF-1 LR3 Being Studied?

IGF-1 LR3 is investigated due to the fact that the IGF-1 signalling pathway has a key role in cellular communication, tissue formation, metabolism and growth factors. Investigators can use IGF-1 LR3 as a model to see how IGF analogues react differently from the natural IGF-1.

The scientific investigation may include: the receptor binding, cell survival pathways, muscle cell model, fibroblast function, cartilage investigation, metabolism, amino acids transportation and cell differentiation. All of the above-mentioned areas are experimental and must not be described as therapeutic effects.

How Does IGF-1 LR3 Work?

The interaction of IGF-1 LR3 with the IGF-1 receptor is usually considered when studying IGF-1 LR3. The activation of the pathway could affect other pathways, such as PI3K/Akt and MAPK pathways, that are usually under investigation in studies on cell growth, survival, and metabolism.

Since IGF-1 LR3 has lower affinity for IGF-binding proteins than natural IGF-1, scientists study whether it affects experimental properties of IGF-1 LR3.

Understanding IGF-1 LR3 Dosage

Discussion on IGF-1 LR3 dosage is only relevant within laboratory research. An IGF-1 LR3 dosage is not prescribed for human use at present. This item should never be used for self-medicating, body building, athletic purposes or for veterinary purposes.

One milligram of vial refers to the total amount of peptides provided. The research concentration will depend on the nature of experiment, assay used, exposure time, solvents used and cell culture type.

IGF-1 LR3 and Research Quality

Quality is an important issue for the studies involving growth factor mimics like IGF-1 LR3. The researchers need to analyze the factors like peptide identity, purity, batch, analysis report, Certificate of Analysis, HPLC results, mass spectroscopy data and storage information.

Reproducibility of studies using peptides requires each vial to have batch information. The storage, manipulation and reconstitution of the vial are other variables that need control.

IGF-1 LR3 in Australia

There has been growing interest in IGF-1 LR3 peptide Australia from researchers doing research on growth-factor signalling pathways and metabolic peptide research. Researchers in Australia should concentrate on research materials that comply with regulations with clear specifications.

IGF-1 LR3 1mg is for research purposes only. It cannot be used for human consumption, injection, therapy, cosmetics, or veterinary use in Australia.

What to Consider Before You Buy IGF-1 LR3

Prior to purchasing IGF-1 LR3 for research in Australia, it is essential to ensure that your supplier can offer you clear specifications about the product.

Critical aspects to examine here are whether the product is indeed a peptide, its quantity, purity details, COA provision, storage, shipping conditions, as well as whether there are any medical or performance claims on the website.

Concerning IGF-1 LR3 1mg, it is essential to examine whether the product will be applicable for your chosen model, as well as whether the concentration is appropriate after dilution.

Safety and Current Research

IGF-1 LR3 is to be used strictly under controlled lab conditions and only by trained professionals. It should be used solely for experimental purposes in research and not be applied anywhere else.

Present-day investigations of IGF-1 LR3 are conducted through experimental signaling pathways and growth factors. Results from studies with cells or animals cannot be considered as evidence of its safety and efficacy in humans.

Frequently Asked Questions

IGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 studied in laboratory research for IGF-1 receptor signalling and cellular pathway activity.

It means the vial contains 1mg of lyophilised IGF-1 LR3 research peptide.

No. IGF-1 LR3 is a modified analogue of IGF-1 with structural changes that may affect binding behaviour and research activity.

It is studied in models involving growth-factor signalling, cell proliferation, metabolic pathways, protein synthesis and receptor activation.

No. There is no approved human dosage for IGF-1 LR3. Any concentration should relate only to controlled laboratory protocols.

IGF-1 LR3 may be supplied as a research material in Australia, but it must be used only for lawful laboratory and scientific purposes.

No. This product is not intended for bodybuilding, sport performance, self-administration or human use.

Batch documentation helps confirm identity, traceability and analytical review for the exact research material used.

Storage should follow the product label and batch documentation, commonly with protection from heat, moisture and light.

No human-use safety claim should be made. IGF-1 LR3 is supplied strictly for research use only.

Notice

IGF-1 LR3 is an investigational peptide intended for scientific research purposes. It should not be presented as an approved therapeutic medicine in Australia. Researchers and organisations should verify the current regulatory requirements applicable to their intended research, importation, possession and supply activities.

Disclaimer

This content is provided for educational, scientific and research-information purposes only. It does not provide medical advice, treatment recommendations or personal dosage instructions. Available evidence concerning IGF-1 LR3 includes preclinical research and limited clinical investigations. Further research is required to better understand its safety, pharmacology and potential efficacy for specific research applications.

References

5 sources
  1. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ.
    Long R3 Insulin-Like Growth Factor-I (IGF-I) Infusion Stimulates Organ Growth but Reduces Plasma IGF-I, IGF-II and IGF Binding Protein Concentrations in the Guinea Pig.
    Journal of Endocrinology. 1995;146(2):247-253.
    PubMed: https://pubmed.ncbi.nlm.nih.gov/7561636/
  2. Dunaiski V, Dunshea FR, Walton PE, Goddard C.
    Long [R3] Insulin-Like Growth Factor-I Reduces Growth, Plasma Growth Hormone, IGF Binding Protein-3 and Endogenous IGF-I Concentrations in Pigs.
    Journal of Endocrinology. 1997;155(3):559-565.
    PubMed: https://pubmed.ncbi.nlm.nih.gov/9488001/
  3. Tomas FM, Knowles SE, Owens PC, et al.
    Insulin-Like Growth Factor-I (IGF-I) Analogue, LR3IGF-I, Attenuates the Loss of Lean Tissue and Fat Associated with Food Restriction in Rats.
    Journal of Endocrinology. 2001.
    PubMed: https://pubmed.ncbi.nlm.nih.gov/11472075/
  4. Prelle K, Stojkovic M, Boxhammer K, Motlik J, Ewald D, Arnold GJ, Wolf E.
    Insulin-Like Growth Factor I (IGF-I) and Long R3IGF-I Differently Affect Development and Messenger Ribonucleic Acid Abundance for IGF-Binding Proteins and Type I IGF Receptors in In Vitro Produced Bovine Embryos.
    Endocrinology. 2001;142(3):1309-1316.
    PubMed: https://pubmed.ncbi.nlm.nih.gov/11181549/
  5. Australian Government, Therapeutic Goods Administration (TGA).
    TGA Strengthens Compliance Focus on Unapproved Peptide Products as Part of Evolving Risk Response.
    Therapeutic Goods Administration. 10 June 2026.
    TGA: https://www.tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products-part-evolving-risk-response
Medically & Scientifically Reviewed By

Dr. Priyanka Goel

Scientific & Medical Content Reviewer

Information last reviewed: 9 Jul 2026

Researchers Also Explore

The products and information offered by Verified Peptides are intended for legitimate laboratory, analytical and scientific research applications only. Products are not for human or veterinary use, and are not therapeutic goods. The results of studies should be interpreted based on the experimental model and the limitations of the existing evidence base.

Product information and educational materials are provided only for research and informational purposes and must not be interpreted as medical advice, diagnosis or treatment.

Disclaimer Our Standards Age Policy Restricted Use Notice
Added to cart
View Cart Checkout